
Cogint (COGT) Stock Forecast & Price Target
Cogint (COGT) Analyst Ratings
Bulls say
Cogent Biosciences Inc. is strategically positioned for significant growth, with 2025 anticipated as a landmark year that may attract merger and acquisition interest. Positive outcomes from the APEX and PEAK trials, along with favorable results from the SUMMIT trial, bolster the potential of bezuclastinib to establish itself as a significant player across multiple malignancies. The company's focus on precision therapies targeting genetically defined diseases, including Systemic Mastocytosis and advanced gastrointestinal stromal tumors, underlines its commitment to improving patient outcomes and enhances its market potential.
Bears say
Cogent Biosciences Inc. has projected a significantly negative financial outlook, with anticipated losses of $2.28 per share for the full year 2025. The company faces multiple risks that could further exacerbate its financial situation, including negative clinical data, slower-than-expected development timelines, and potential setbacks in both later-stage and earlier-stage trials. Additionally, concerns regarding regulatory approvals and commercial success highlight ongoing challenges, contributing to overall uncertainty about future performance and dilutive risks for shareholders.
This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.
Cogint (COGT) Analyst Forecast & Price Prediction
Start investing in Cogint (COGT)
Order type
Buy in
Order amount
Est. shares
0 shares